⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for gist tyrosine kinase inhibitor

Every month we try and update this database with for gist tyrosine kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTNCT03465722
GIST
avapritinib
regorafenib
18 Years - Blueprint Medicines Corporation
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)NCT05160168
Gastrointestina...
Neoplasms, Conn...
Neoplasms, Conn...
Neoplasms by Hi...
Neoplasms
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
THE-630
18 Years - Theseus Pharmaceuticals
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsNCT02508532
Gastrointestina...
Other Relapsed ...
Avapritinib
18 Years - Blueprint Medicines Corporation
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTNCT03465722
GIST
avapritinib
regorafenib
18 Years - Blueprint Medicines Corporation
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: